Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome

Blood

Volumn 118, Issue 9, 2011, Pages 2609-2617

  Lee, Kyoo Hyung ^a   Lee, Je Hwan ^a   Lee, Jung Hee ^a   Kim, Dae Young ^a   Seol, Miee ^a   Lee, Young Shin ^a   Kang, Young Ah ^a   Jeon, Mijin ^a   Hwang, Hyun Ju ^a   Jung, Ah Rang ^a   Kim, Sung Han ^a   Yun, Sung Cheol ^a   Shin, Ho Jin ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; LEUKAPHERESIS; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOTHER; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGENY; REDUCED INTENSITY CONDITIONING; SIBLING;

EID: 80052397679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-339838     Document Type: Article

References (36)

1. Godley L.A., Van Besien K. The next frontier for stem cell transplantation: Finding a donor for all. JAMA. 2010;303(14):1421-1422.
2. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765-771. (Pubitemid 15232310)
3. Powles R.L., Morgenstern G.R., Kay H.E., et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612-615. (Pubitemid 13152341)
4. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89(10):3864-3872. (Pubitemid 27227113)
5. Mead A.J., Thomson K.J., Morris E.C., et al. HLAmismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reducedintensity conditioning. Blood. 2010;115(25):5147-5153.
6. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stemcell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol. 2010;11(7):653-660.
7. Rizzieri D.A., Storms R., Chen D.F., et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1107-1114.
8. Yoon S.R., Lee Y.S., Yang S.H., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: A feasibility study. Bone Marrow Transplant. 2010;45(6):1038-1046.
9. Beelen D.W., Ottinger H.D., Elmaagacli A., et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: A prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood. 1997;90(12):4725-4735. (Pubitemid 28007185)
10. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206. (Pubitemid 35332066)
11. Vanclee A., Lutgens L.C., Oving E.B., et al. Keratinocyte growth factor ameliorates acute graft-versushost disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant. 2005;36(10):907-915. (Pubitemid 41655619)
12. Sandmaier B.M., Fukuda T., Gooley T., Yu C., Santos E.B., Storb R. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Exp Hematol. 2003;31(2):168-175. (Pubitemid 36184642)
13. Cina R.A., Wikiel K.J., Lee P.W., et al. Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation. Transplantation. 2006;81(12):1677-1685. (Pubitemid 43948301)
14. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12(10):1073-1084.
15. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25(6):690-697. (Pubitemid 350002925)
16. Luznik L., O'Donnell P.V., Symons H.J., et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. (Pubitemid 351664058)
17. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
18. Lee K.H., Lee J.H., Kim D.Y., et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant. 2009;15(1):61-72.
19. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
20. McDonald G.B., Hinds M.S., Fisher L.D., et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-267. (Pubitemid 23046384)
21. Sullivan K. Graft-vs-host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation (3rd ed). Malden, MA: Blackwell; 2004:635-664.
22. Kim D.Y., Lee J.H., Kim S.H., et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant. 2010;45(7):1174-1180.
23. Klein J.P., Moeschberger, M.L. Survival Analysis. Techniques of Censored and Truncated Data (2nd ed). New York, NY: Springer-Verlag; 2003.
24. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
25. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12(8):828-836. (Pubitemid 44070671)
26. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):495-509.
27. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353(13):1321-1331. (Pubitemid 41362700)
28. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: Effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482-489.
29. Lee K.H., Choi S.J., Lee J.H., et al. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. Am J Hematol. 2011;86(5):399-405.
30. Park M.H., Hwang Y.S., Park K.S., et al. HLA haplotypes in Koreans based on 107 families. Tissue Antigens. 1998;51(4):347-355.
31. Oh H., Loberiza F.R. Jr, Zhang M.J., et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105(4):1408-1416. (Pubitemid 40223655)
32. Chen P.M., Tzeng C.H., Fan F.S., Hsieh R.K., Wei C.H. Bone marrow transplantation in Taiwan: Low incidence of acute GVHD in patients with hematologic malignancies and severe aplastic anemia. Bone Marrow Transplant. 1994;13(6):709-711. (Pubitemid 24195780)
33. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.
34. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood. 2007;110(1):433-440. (Pubitemid 47026866)
35. Whang D.H., Park H., Yoon J.A., Park M.H. Haplotype analysis of killer cell immunoglobulin-like receptor genes in 77 Korean families. Hum Immunol. 2005;66(2):146-154. (Pubitemid 40208202)
36. Aizawa S., Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation. 1991;52(5):885-889.